Johnson & Johnson (JNJ) is a Healthcare company in the Drug Manufacturers General industry. It has a market capitalization of $664.95B, a trailing price-to-earnings ratio of 25.9 and a free-cash-flow yield of 2.9%. Over the most recent reported fiscal year, revenue grew 6.0% and free cash flow per share grew 6.9%. Nama's AI scorecard rates it Buy, 6.8 out of 10. On 12-month momentum it ranks in the leading band of its market.
AI scorecard
Buy · 6.8/10
Positive, at the low end of Buy. As of Nov 7, 2026.
Momentum
Leading · +38.2% over 12 months ex. last
Top 20% of its market on the past year's steady rise.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-2.0%
How far the last close sits under the highest price of the past five years.
Market cap
$664.95B
Trailing P/E
25.9
Price / book
8.2
Price / sales
6.7
FCF yield
2.9%
Dividend yield
1.9%
Gross margin
67.6%
Operating margin
25.7%
Net margin
16.2%
Revenue growth (YoY)
+6.0%
Revenue growth (3-yr annual)
+5.6%
EPS growth (YoY)
+8.1%
FCF/share growth (YoY)
+6.9%
Beta
0.2
Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers General
JNJ earnings
Next report: Jan 26, 2027 (Q4 2026, EPS estimate $2.92).
Beat the EPS estimate in 3 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Oct 13, 2026
$2.59
$2.52
+2.8%
$25.40B
Q2 2026
Jul 15, 2026
$2.90
$2.85
+1.8%
$25.31B
Q1 2026
Apr 14, 2026
$2.70
$2.68
+0.8%
$24.06B
Q4 2025
Jan 21, 2026
$2.46
$2.46
+0.0%
$24.56B
JNJ analyst price target
Median target $280.50 from 22 analysts, ranging $190.00 – $320.00.
Nama's AI scorecard currently rates Johnson & Johnson Buy (6.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is JNJ's P/E ratio?
Johnson & Johnson trades at a trailing price-to-earnings ratio of 25.9.
When does JNJ report earnings?
Johnson & Johnson's next scheduled report is on Jan 26, 2027. Analysts expect EPS of $2.92.
What is the JNJ price target?
The median analyst price target from 22 analysts is $280.50, with a range of $190.00 – $320.00.
Is JNJ Shariah compliant?
Nama's AAOIFI-style screen reads Johnson & Johnson as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.